New York Attorney Now Accepting Januvia, Janumet, Byetta or Victoza-Related Pancreatic Cancer Cases
Commack, NY (PRWEB) November 05, 2013 -- New York law firm Rudolph F. X. Migliore, P.C. has announced they are now accepting cases on behalf of individuals who used the type-2 diabetes medication Januvia, Janumet, Byetta or Victoza and who later developed pancreatic or thyroid cancer.
Januvia is the brand name for sitagliptin (also marketed as Janumet), a medication doctors prescribe for diabetics to help control blood sugar levels.
The FDA originally issued a warning about Januvia risks in 2009. In 2011, researchers found that individuals who have taken Januvia are six times more likely to develop pancreatitis and the risk of pancreatic cancer increased by 270% and the risk of thyroid cancer by 148% (*1). After the Journal for the American Medical Association (*2) published a study in February 2013 that showed drugs like Januvia could double the risk for pancreatitis and lead to pancreatic cancer and kidney failure, the FDA (*3) issued a new Januvia warning.
Rudolph Migliore, stated, "While modern medicine has done much to improve the quality of our lives, when defective products or prescription drugs cause unintended consequences, patients suffer unnecessarily from serious injuries."
If you or someone you care about was diagnosed with pancreatic cancer after taking the prescription drug Januvia, Janumet, Byetta or Victoza, it is important to seek legal advice as soon as possible. Rudolph F. X. Migliore, P.C. offers a free case evaluation to find out if you have grounds for a claim to seek damages. Call (631) 543-3663 or toll free at 1-888-980-RFXM to arrange a consultation.
Extensive product liability experience gives attorney Rudolph F.X. Migliore the expertise needed to handle complicated prescription drug cases. The Migliore law firm has represented clients in wide range of defective product and drug cases since 1977 and has worked with nationally recognized co-counsel to reach successful settlements for clients. Visit: http://www.diabetesdrugproblems.com
*1 USA Today (September 23, 2011)
*2 Bloomberg News (Feb 25, 2013)
*3 The Food and Drug Administration (March 2012)
Rudy Migliore, Rudolph F.X. Migliore, P.C., http://www.MiglioreLaw.com, +1 6315433663, [email protected]
Share this article